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ABSTRACT
Endometriosis is a chronic inflammatory disorder asso-
ciated with pelvic pain and infertility. Because surgical 
and medical therapies control symptoms, but it is hard to 
cure completely endometriosis, long term of pharmaco-
logic management is necessary. Norethisterone (NET), 
one of progestins, has safety profile and advantage that 
allow long-term use. In this preliminary report, we 
showed the efficacy of NET in 6 patients with endome-
triosis. The size of ovarian endometrioma was decreased 
after treatment with NET for 6 months, and all patients 
were relieved from dysmenorrhea pain within 6 months, 
suggesting that NET would be a suitable medication to 
treat endometriosis.
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Endometriosis occurs in 10% of women in their repro-
ductive age. Over recent years, it is estimated to be in-
creasing due to late marriage and delayed childbearing 
in Japan. This disorder causes dysmenorrhea, infertility, 
and chronic pelvic pain. Ovarian endometrioma is a 
common endometriotic lesion, affecting 55% of patients 
with endometriosis.1 Management of endometrioma 
includes surgical and medical treatment, taking into 
consideration symptoms, desire for childbearing, lesion 
dimension, past treatment history, and ovarian reserve.
 The commonly used medications to treat endo-
metriosis are non-steroidal anti-inflammatory drugs 
(NSAIDs), low dose oral contraceptive pills (OCPs), 
GnRH agonists (GnRHa), and progestins, such as NET 
and dienogest (DNG). Hormonal drugs can control 
ovulation or menstrual cycle, in addition to possessing 
beneficial effects against pain. Because the medication 
for endometriosis usually takes long time, the drugs with 
favorable safety profile, efficacy, tolerability and cost 
profile should be preferable.
 Recently, OCP as a first-line treatment is a simple 
way to manage endometriosis. The OCPs containing 
synthetic estrogen and progestin are effective for pelvic 
pain relief and control of endometriotic lesions. Only one 
randomized, controlled trial (RCT), which demonstrated 
the efficacy of an OCP (norethisterone/ethinylestradiol: 
NET/EE: 1 mg/35 μg) for dysmenorrhea associated with 
endometriosis and the reduction of the endometrioma 
volume larger than 3 cm in diameter after 4 cycles of 
OCP, has been reported. The OCP treatment resulted in 
about a 50% reduction in dysmenorrhea as determined 
by verbal rating pain scoring.2
 However, there are some practical limitations to use 
the OCPs. The critical issues in managing endometriosis 
are side effects and recurrence of symptoms that require 
long-term or repeated courses of medication. For in-
stance, OCPs are contraindicated in patients older than 
35 years who smoke or have the risk of venous throm-
boembolism, whereas NET confers no increased risk. 
Moreover, the long-term use of OCPs for several years 
may result in endometrial thinning that is nonresponsive 
to estrogen.3 This adverse effect of long-term use may be 
crucial for women with endometriosis who want to con-
ceive.
 In contrast to OCP, several investigators indicated 
the efficacy of progestins, such as NET or DNG in alle-
viating the chronic pelvic pain and dysmenorrhea asso-
ciated with endometriosis.4–6 NET, which is known and 
used as norethindrone or norethisterone acetate (NETA) 
in the foreign countries, is a steroidal progestin of the 
19-nortestosterone group with additional weak andro-
genic and estrogenic activity. These compounds induce 
atrophy of eutopic and ectopic endometrium, have an-
ti-inflammatory and proapoptotic properties. In the case 
of a contraindication to estrogen, OCPs could be the 
therapy of endometriosis-associated pain, followed by 
progestin-only treatment. In this study, we focused the 
efficacy of NET in the development of ovarian endome-
triomas and endometriosis-associated pain.
PATIENT REPORT
Study design
After obtaining informed consent, we recruited 6 wom-
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en with unilateral ovarian endometriomas from January 
to December 2015. Patient inclusion criteria included 
women 39 to 48 years old; regular menstrual cycles (28 
± 2 d); ovarian endometrioma diagnosed by transvaginal 
ultrasound or magnetic resonance imaging; moderate or 
severe dysmenorrhea; and no hormonal or surgical treat-
ment for endometriosis within 1 year of entry into this 
study. The degree of dysmenorrhea was evaluated ac-
cording to a visual analogue scale (VAS) from 0 mm “no 
pain” to 100 mm “the worst pain you could imagine.” 
NET (5 mg/d: Norluten; Fuji Pharma, Tokyo, Japan) was 
administered every day for at least 6 months. The use 
of other hormonal treatments for pain and any kinds of 
analgesics was not allowed. The characteristics of this 
study population are shown in Table 1.
Patient monitoring
In this protocol, each patient underwent a pre-recruit-
ment evaluation, consisting of a general medical and 
gynecologic history, physical and pelvic examination, 
patient evaluation of pain, and review of the menstrual 
records. Blood was drawn for pretreatment clinical lab-
oratory determinations, including hematologic and bio-
chemical tests, and CA125. Patients were followed every 
4 weeks to evaluate pain, side effects, and other health 
concerns. After 6 four-week treatments, efficacy of NET 
was evaluated. Main outcome measures were the final 
measurement of the volume of ovarian endometrioma 
and the VAS score during treatment. The measures 
recorded at the initiation of NET therapy prescription 
were considered the baseline (pretreatment). Clinical 
and ultrasound examinations were performed at baseline 
and after 6, 9, and 12 months of treatment. Total vol-
ume of the endometrioma was obtained by calculating 
the three-dimensional diameters on a longitudinal and 
sagittal scan. When the endometrioma was multiocular, 
the size of largest cyst was measured. Data are shown as 
mean ± SD.
Analysis data
The characteristics of 6 patients with ovarian endometri-
omas were shown in Table 1. Ages ranged from 39 to 48 
years (43.3 ± 3.8 years). Mean body mass index (BMI) 
of patients was 21.1 ± 2.0 kg/m2. All patients had regular 
menstrual cycles. Five patients had never experienced 
childbirth. The mean largest diameter of ovarian endo-
metrioma was 4.6 ± 2.4 cm (range: 1.1 to 8.3 cm) and 
pretreatment CA125 value was 21.9 ± 8.6 U/mL (range: 
11.3 to 33.5 U/mL). 
 The maximum diameter of ovarian endometrioma 
was slightly decreased by NET treatment for 6 months 
(Mean: 3.9 cm vs. pretreatment: 4.6 cm). Accordingly, 
NET treatment for 6 months exhibited 37.2% reduc-
tion of volume of endometrioma (Mean: 37.9 cm3 vs. 
pretreatment: 60.5 cm3). After 9, and 12 months, the re-
duction rates of endometriomas were almost as much as 
those after 6 months. Before NET treatment, the mean 
of VAS scores indicating dysmenorrhea pain was 65.2 ± 
20.4 mm. The state of amenorrhea and “no pain” were 
verified in 5 patients within 3 months, and in 1 patient at 
6 months after NET treatment. Prior to the NET therapy, 
5 patients were not treated with any drugs for endome-
triosis, and 1 patient was performed laparoscopic cystec-
tomy for right ovarian endometrioma 12 years ago. Two 
patients (No. 2 and 5) were followed up for the expectant 
management until NET therapy, and 3 patients (No. 1, 3 
Table 1. Summary for 6 cases
Case 1 2 3 4 5 6
Age (years) 39 48 39 44 47 43
G/P 0/0 0/0 0/0 0/0 1/1 0/0
VAS (mm) 52 100 58 80 50 51
Volume of endometrioma (cm3)
Pre-treatment 236.3 17.3 43.3 0.55 9.3 56.6
After 6 months 130.2 2.9 42.0 0.29 5.0 35.5
Incidence of amenorrhea (months) 6 3 3 3 3 1
Duration of NET therapy (months) 26 20 18 15 14 9
CA125 (U/mL) 29.8 11.3 20.1 22.4 33.5 14.4
Presence of adenomyosis (+) (+) (+) (+)
Age at diagnosis (years) 39 43 39 32 37 43
Other treatment until NET (–) (–) (–) Cystectomy (–) (–)
G/P, gravidity and parity; NET, norethisterone; VAS, visual analogue scale.
184
F. Taniguchi et al.
and 6) were initially treated with NET after the diagno-
sis of endometriosis.
 No de novo development of ovarian endometriomas 
occurred in this follow-up period. No serious adverse 
events related to NET use were observed. For example, 
the abnormal liver function results and skin problems 
did not occur.
DISCUSSION
Our present data revealed that NET was effective in 
treating dysmenorrhea, resulted in amenorrhea for at 
least 6 months, and reduced the size of ovarian endome-
triomas. It appears that women with endometriosis may 
be controlled well with oral progestin-only treatment as 
one of the first-line therapies. Progestin alone, in milli-
gram per day doses, generally inhibit ovulation,7, 8 and 
induce amenorrhea, which could prevent dysmenorrhea. 
The decrease of gonadotropin secretion induced by the 
action of potent progestins will result in a relatively hy-
poestrogenic state that could help suppress endometrio-
sis lesions, and certainly should prevent progression of 
this disease.
 Progestins do not increase the thrombotic risk, and 
have the anti-inflammatory and anti-angiogenic activ-
ity in endometriotic tissues. NET or DNG appear to 
be equally effective in alleviating pain and decreasing 
lesion size in endometriosis.4 NET also has androgenic 
activity, whereas DNG is anti-androgenic. These two 
progestins do not exhibit substantial glucocorticoid 
or anti-mineralcorticoid actions, which several other 
hormonal drugs possess. Progestins themselves may 
have a positive effect on bone formation.9 A hypothetic 
advantage of NET over DNG is that NET is partly me-
tabolized to estrogens. This should prevent bone loss 
during prolonged periods of treatment.10 In terms of 
these progestins, Vercellini et al. indicated the recent 
data to assess the proportion of patients satisfied with 
the treatment of NETA (2.5 mg per d, for 90 d) or DNG 
(2 mg per day, for 90 d) as the first-line progestin for 
symptomatic endometriosis. The overall satisfaction 
with treatment, such as pain relief, psychological status, 
and sexual function, was almost identical in both drugs.4
 On the other hand, OCPs suppress ovulation and 
reduce the growth of endometrial tissue, thus reducing 
both menstrual flow and prostaglandins production. 
OCPs’ possible side effects, such as headache, nausea, 
and atypical uterine bleeding, are known. In two recent 
studies, a significant reduction in the diameter of endo-
metrioma after 6 months of an ultra-low dose OCP con-
taining DRSP/EE (drospirenone/EE: 3 mg/20 μg) was 
shown.11 We also showed that it alleviates dysmenorrhea, 
synthesizes proinflammatory cytokines, and preserves 
ovarian reserve.11 
 NET and DNG did not appear to differ with regard 
to safety profiles, but their cost did: DNG was more ex-
pensive compared with NET (approximately 100,000 vs. 
4,000 Japanese yen, per a year). However, the patients 
were also informed that NET or DNG induce only tem-
porary pain relief during treatment, and are not expected 
definitive cure of endometriosis. Even if the long-term 
management with these drugs is done, it is difficult to be 
eliminated completely the lesions of endometriosis. For 
the future, the long-term safety of these progestins re-
mains to be investigated, because the medical treatments 
for endometriosis may be needed for years.
 In conclusion, current data suggest that NET is a 
promising treatment not only for endometriosis-associ-
ated dysmenorrhea but it also reduces the size of ovarian 
endometriomas. Oral progestins alone can be used at 
any age, do not increase the risk of thrombosis, and are 
capable of inhibiting ovulation and inducing amenorrhea 
with very few side effects.
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